Skip to main content

XTL Biopharmaceuticals Ltd.

corporate_fare Company Profile

XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed XTLB - Latest Insights

XTLB
Apr 29, 2026, 9:07 AM EDT
Filing Type: 6-K
Importance Score:
9
XTLB
Mar 20, 2026, 4:11 PM EDT
Filing Type: 6-K
Importance Score:
7
XTLB
Mar 10, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
9
XTLB
Feb 27, 2026, 4:34 PM EST
Filing Type: 6-K
Importance Score:
9
XTLB
Feb 24, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
9
XTLB
Feb 23, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
9
XTLB
Feb 17, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
7
XTLB
Jan 28, 2026, 8:58 AM EST
Filing Type: 6-K
Importance Score:
7
XTLB
Jan 23, 2026, 4:15 PM EST
Filing Type: 6-K
Importance Score:
9
XTLB
Jan 23, 2026, 4:15 PM EST
Filing Type: 6-K
Importance Score:
9
XTLB
Jan 13, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
9
XTLB
Jan 13, 2026, 7:30 AM EST
Filing Type: 6-K
Importance Score:
8